Long-term safety study of idecabtagene vicleucel for multiple myeloma in Korea
Treatments studied
Part of Blood & lymphatic, Cancer, Heart & circulation, Immune system & allergy clinical trials.
This study follows up on Korean adults with multiple myeloma who received the CAR T-cell therapy idecabtagene vicleucel (also called Ide-cel) in a previous trial (KarMMa-9) and did not have an optimal response after a stem cell transplant. The goal is to monitor long-term safety.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You are 19 years old or older
- You are Korean and have newly diagnosed multiple myeloma
- You received idecabtagene vicleucel (Ide-cel) in the KarMMa-9 trial after a stem cell transplant that didn't work as well as hoped
- You agree to take part in long-term follow-up in Korea
- You must not have disagreed with long-term follow-up in the previous trial
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This registry study will follow people who have received the CAR T-cell therapy equecabtagene autoleucel to monitor their long-term health and outcomes. It is open to those who completed or withdrew from an earlier study of this treatment.
This trial tests a one-time cell therapy called ciltacabtagene autoleucel (a CAR-T treatment) in people who have newly diagnosed multiple myeloma and are not eligible for a stem cell transplant. It aims to see if this treatment is safe and effective as an early therapy.
This study tests a new CAR-T cell therapy called Eque-cel for people with multiple myeloma that no longer responds to lenalidomide. It aims to see if this treatment can help control the disease after 1-2 prior therapies.
This trial tests a combination of three drugs (elotuzumab, iberdomide, and dexamethasone) for multiple myeloma that has come back after treatment with a type of CAR T-cell therapy called ide-cel. It aims to see if this new combination can help people who have already tried several other treatments.
This study looks at late side effects that may happen after CAR-T therapy (cilta-cel) for multiple myeloma. It aims to better understand these delayed toxicities so doctors can manage them more effectively.
This trial tests a new CAR-T cell therapy (called arlocabtagene autoleucel) combined with other drugs for multiple myeloma that has returned or stopped responding. It aims to find a safe and effective dose while tracking how well the treatment works.
Hear when a new Multiple myeloma trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.